Related Experiment Video

Updated: Aug 8, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

David B Agus1, Robert W Akita, William D Fox

  • 1Cedars-Sinai Prostate Cancer Center, Los Angeles, California 90048, USA.

Cancer Cell
|September 3, 2002
PubMed

Insights

Monoclonal antibody 2C4 targets ErbB2 (Epidermal Growth Factor Receptor family member 2) as a coreceptor. This antibody inhibits tumor growth in breast and prostate models by blocking ErbB2 signaling pathways.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • ErbB2 (Epidermal Growth Factor Receptor family member 2) is a key coreceptor in the ErbB receptor family, interacting with EGFR, ErbB3, and ErbB4.
  • ErbB2 lacks a direct ligand-binding domain and its function is primarily mediated through its coreceptor role.

Discussion:

  • The monoclonal antibody 2C4 sterically hinders ErbB2 recruitment into ErbB ligand complexes, effectively inhibiting ErbB2 signaling.
  • 2C4 demonstrates efficacy in blocking ligand-dependent ErbB2 signaling across systems with varying ErbB2 expression levels.
  • The antibody is particularly effective in inhibiting heregulin-mediated ErbB3-ErbB2 signaling due to ErbB3's inactive tyrosine kinase domain.

Key Insights:

  • Monoclonal antibody 2C4 targets ErbB2's coreceptor function, a novel therapeutic strategy.
  • 2C4 effectively inhibits both ErbB2 and ErbB3-ErbB2 signaling pathways.
  • Treatment with 2C4 significantly inhibits the in vitro and in vivo growth of breast and prostate tumor models.

Outlook:

  • Further investigation into 2C4 as a targeted therapy for ErbB2-overexpressing cancers.
  • Exploring combination therapies involving 2C4 to enhance treatment outcomes.
  • Investigating the precise molecular mechanisms of 2C4-mediated growth inhibition in various tumor types.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: